Small-molecule therapies targeting Sigma-1 and -2 Receptors (σ1R and σ2R, respectively), offer a promising approach to treat AD (De Vos et al., 2012; Magalhaes Rebelo et al., 2020). Here, TMEM97 is linked to Alzheimer disease.